Compare IPI & KMDA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | IPI | KMDA |
|---|---|---|
| Founded | 2000 | 1990 |
| Country | United States | Israel |
| Employees | N/A | N/A |
| Industry | Mining & Quarrying of Nonmetallic Minerals (No Fuels) | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 380.0M | 385.3M |
| IPO Year | 2008 | N/A |
| Metric | IPI | KMDA |
|---|---|---|
| Price | $28.21 | $7.03 |
| Analyst Decision | Strong Sell | Strong Buy |
| Analyst Count | 1 | 3 |
| Target Price | ★ $23.00 | $13.00 |
| AVG Volume (30 Days) | ★ 138.4K | 102.2K |
| Earning Date | 11-05-2025 | 11-10-2025 |
| Dividend Yield | N/A | ★ 2.83% |
| EPS Growth | N/A | ★ 30.41 |
| EPS | N/A | ★ 0.35 |
| Revenue | ★ $222,728,000.00 | $174,787,000.00 |
| Revenue This Year | $23.99 | $14.79 |
| Revenue Next Year | N/A | $10.74 |
| P/E Ratio | ★ N/A | $19.87 |
| Revenue Growth | 7.93 | ★ 10.36 |
| 52 Week Low | $20.86 | $5.54 |
| 52 Week High | $39.01 | $9.16 |
| Indicator | IPI | KMDA |
|---|---|---|
| Relative Strength Index (RSI) | 62.49 | 51.72 |
| Support Level | $26.04 | $6.97 |
| Resistance Level | $29.40 | $7.45 |
| Average True Range (ATR) | 1.13 | 0.16 |
| MACD | 0.27 | 0.00 |
| Stochastic Oscillator | 72.71 | 52.57 |
Intrepid Potash Inc produces and sells potash and potash byproducts in three main product segments: Potash, Trio, and Oilfield Solutions. The Potash segment produces and sells potash to the agricultural industry as a fertilizer input, the industrial market as a component of oil and gas drilling fluid, and the animal feed market as a nutrient supplement. The Trio segment produces and sells specialty fertilizer that consists of potassium, sulfate, and magnesium and is mined from langbeinite ore. The oilfield solutions segment offers water, high-speed potassium chloride mixing services, saltwater disposal services, and trucking services. The vast majority of revenue is generated in the United States, which is also the location of the firm's production facilities.
Kamada Ltd is a drug-focused, plasma-derived protein therapeutics company. It is involved in the business of developing, producing, and marketing specialty therapeutics using protein purification proprietary technology. Its product portfolio consists of Glassia, Bramitob, Foster, Ixiaro, Factor-IX, and others. The company has two segments namely, the Proprietary Products segment and the Distribution segment. It derives the majority of its revenue from the Proprietary products segment. The firm categorizes its products in Lung Disease, Vaccines, Haemophilia, Immunoglobulins, Critical care, and Diagnostics.